These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21786492)

  • 1. Biological disease modifying anti-rheumatic drugs.
    Cranwell-Bruce LA
    Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trials reveal promising options for treating juvenile rheumatoid arthritis.
    Hampton T
    JAMA; 2008 Jan; 299(1):27-8. PubMed ID: 18167400
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
    Francis S; Block MJ
    Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
    [No Abstract]   [Full Text] [Related]  

  • 7. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto.
    Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ
    Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of rheumatoid arthritis (RA) biotherapies in France.
    Maravic M
    Joint Bone Spine; 2010 Jul; 77(4):319-24. PubMed ID: 20493751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 12. Questions and answers in 2008 about biologics in rheumatoid arthritis.
    Weinblatt ME
    J Rheumatol; 2008 Sep; 35(9):1878-81. PubMed ID: 18785296
    [No Abstract]   [Full Text] [Related]  

  • 13. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
    Rose E; Lequerré T; Pouplin S; Daragon A; Le Loët X; Vittecoq O
    Joint Bone Spine; 2012 Jul; 79(4):421-2. PubMed ID: 22512937
    [No Abstract]   [Full Text] [Related]  

  • 15. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)].
    Rubio-Terrés C; Ordovás Baines JP; Pla Poblador R; Martínez Nieto C; Sánchez Garre MJ; Rosado Souvirón MA; Sierra Muñoz A; Sánchez Mateo M;
    Farm Hosp; 2007; 31(2):78-92. PubMed ID: 17590116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological therapy treatment of juvenile idiopathic arthritis].
    Herlin T
    Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effectiveness of TNF antagonists in routine clinical practice and costs].
    Prokes M
    Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
    Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
    Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.